{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:29:27Z","timestamp":1770434967509,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2009,5,8]],"date-time":"2009-05-08T00:00:00Z","timestamp":1241740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1186\/1752-1947-3-7560","type":"journal-article","created":{"date-parts":[[2009,6,5]],"date-time":"2009-06-05T14:52:42Z","timestamp":1244213562000},"source":"Crossref","is-referenced-by-count":12,"title":["Visual hallucinations associated with varenicline: a case report"],"prefix":"10.1186","volume":"3","author":[{"given":"B Mahendri","family":"Raidoo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric C","family":"Kutscher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,8]]},"reference":[{"key":"705_CR1","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1111\/j.1368-5031.2006.00955.x","volume":"60","author":"J Foulds","year":"2006","unstructured":"Foulds J: The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline. Int J Clin Pract. 2006, 60: 571-576. 10.1111\/j.1368-5031.2006.00955.x.","journal-title":"Int J Clin Pract"},{"key":"705_CR2","unstructured":"Chantix TM: Pfizer Inc, 10.1176\/appi.ajp.2007.07020326."},{"key":"705_CR3","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1176\/appi.ajp.2007.07020326","volume":"164","author":"R Freedman","year":"2007","unstructured":"Freedman R: Exacerbation of schizophrenia by varenicline. Am J Psychiatry. 2007, 164: 1269-10.1176\/appi.ajp.2007.07020326.","journal-title":"Am J Psychiatry"},{"key":"705_CR4","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1176\/appi.ajp.2007.07010173","volume":"164","author":"I Kohen","year":"2007","unstructured":"Kohen I, Kremen N: Varenicline-induced manic episode in a patient with bipolar disorder. Am J Psychiatry. 2007, 164: 1270-10.1176\/appi.ajp.2007.07010173.","journal-title":"Am J Psychiatry"},{"key":"705_CR5","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1345\/aph.1K511","volume":"42","author":"A Morstad","year":"2008","unstructured":"Morstad A, Kutscher E, Kennedy W, Carnahan R: Hypomania with agitation associated with varenicline use in bipolar II disorder. Ann Pharmacother. 2008, 42: 288-10.1345\/aph.1K511.","journal-title":"Ann Pharmacother"},{"key":"705_CR6","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1001\/jama.296.1.56","volume":"296","author":"DE Jorenby","year":"2006","unstructured":"Jorenby DE, Taylor Hays J, Rigotti NA, Azoulay S, Watsky EJ, Williams KE, Billing CB, Gong J, Reeves KR, for the Varenicline Phase 3 Study Group: Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation a randomized controlled trial. JAMA. 2006, 296: 56-63. 10.1001\/jama.296.1.56.","journal-title":"JAMA"},{"key":"705_CR7","unstructured":"US Food and Drug Administration: MedWatch."},{"key":"705_CR8","unstructured":"Moore TJ, Cohen MR, Furberg CD: Strong safety signal seen for new varenicline risks: The Institute for Safe Medication Practices."},{"key":"705_CR9","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1360-0443.2007.02083.x","volume":"103","author":"JA Stapleton","year":"2007","unstructured":"Stapleton JA, Watson L, Spirling LI, Smith R, Milbrandt A, Ratcilffe M, Sutherland G: Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement and an evaluation in those with mental illness. Addiction. 2007, 103: 146-154. 10.1111\/j.1360-0443.2007.02083.x.","journal-title":"Addiction"},{"key":"705_CR10","first-page":"265","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 2000, American Psychiatric Association, 265-267. 4","edition":"4"},{"key":"705_CR11","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","volume":"30","author":"CA Naranjo","year":"1981","unstructured":"Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, Janecek E, Domecq C, Greenblatt DJ: A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981, 30: 239-245. 10.1038\/clpt.1981.154.","journal-title":"Clin Pharmacol Ther"},{"key":"705_CR12","first-page":"CD006103","volume-title":"Cochrane Database of Systematic Reviews","author":"K Cahill","year":"2007","unstructured":"Cahill K, Stead LF, Lancaster T: Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews. 2007, CD006103-"},{"key":"705_CR13","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1001\/archinte.166.15.1553","volume":"166","author":"JF Etter","year":"2006","unstructured":"Etter JF: Cytisine for smoking cessation. A literature review and a meta-analysis. Arch Intern Med. 2006, 166: 1553-1559. 10.1001\/archinte.166.15.1553.","journal-title":"Arch Intern Med"},{"key":"705_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1001\/jama.296.1.47","volume":"296","author":"D Gonzales","year":"2006","unstructured":"Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR, for the Varenicline Phase 3 Study Group: Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006, 296: 47-55. 10.1001\/jama.296.1.47.","journal-title":"JAMA"},{"key":"705_CR15","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/archinte.166.15.1571","volume":"166","author":"C Oncken","year":"2006","unstructured":"Oncken C, Gonzales D, Nides M, Rennard SI, Watsky EJ, Billing CB, Anziano R, Reeves KR, for the Varenicline Study Group: Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation. Arch Intern Med. 2006, 166: 1571-1577. 10.1001\/archinte.166.15.1571.","journal-title":"Arch Intern Med"},{"key":"705_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1016\/j.schres.2008.05.002","volume":"103","author":"SH Fatemi","year":"2008","unstructured":"Fatemi SH: Varenicline efficacy and tolerability in a subject with schizophrenia. Schizophr Res. 2008, 103: 328-329. 10.1016\/j.schres.2008.05.002.","journal-title":"Schizophr Res"},{"key":"705_CR17","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.4088\/JCP.v69n0620a","volume":"69","author":"AE Evins","year":"2008","unstructured":"Evins AE, Goff DC: Varenicline treatment for smokers with schizophrenia: a case series. J Clin Psychiatry. 2008, 69: 1016-10.4088\/JCP.v69n0620a.","journal-title":"J Clin Psychiatry"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1752-1947-3-7560\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-3-7560.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-3-7560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1752-1947-3-7560.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T20:19:04Z","timestamp":1548101944000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/1752-1947-3-7560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,8]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["705"],"URL":"https:\/\/doi.org\/10.1186\/1752-1947-3-7560","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,8]]},"article-number":"7560"}}